Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth In Vivo than Either Drug Alone.

Tran LNK, Kichenadasse G, Morel KL, Lavranos TC, Klebe S, Lower KM, Ormsby RJ, Elliot DJ, Sykes PJ.

In Vivo. 2019 Jan-Feb;33(1):99-108. doi: 10.21873/invivo.11445.


The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer.

Tran LNK, Kichenadasse G, Butler LM, Centenera MM, Morel KL, Ormsby RJ, Michael MZ, Lower KM, Sykes PJ.

Mol Cancer Ther. 2017 Dec;16(12):2689-2700. doi: 10.1158/1535-7163.MCT-17-0074. Epub 2017 Aug 11.


Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.

Kortenhorst MS, Isharwal S, van Diest PJ, Chowdhury WH, Marlow C, Carducci MA, Rodriguez R, Veltri RW.

Mol Cancer Ther. 2009 Apr;8(4):802-8. doi: 10.1158/1535-7163.MCT-08-1076.


Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.

Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA.

Prostate. 2007 Jul 1;67(10):1099-110.


Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.

Hudak L, Tezeeh P, Wedel S, Makarević J, Juengel E, Tsaur I, Bartsch G, Wiesner C, Haferkamp A, Blaheta RA.

Prostate. 2012 Dec 1;72(16):1719-35. doi: 10.1002/pros.22525. Epub 2012 Apr 2.


Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth.

Yang F, Song L, Wang H, Wang J, Xu Z, Xing N.

PLoS One. 2015 May 26;10(5):e0128277. doi: 10.1371/journal.pone.0128277. eCollection 2015.


Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.

Xia Q, Sung J, Chowdhury W, Chen CL, Höti N, Shabbeer S, Carducci M, Rodriguez R.

Cancer Res. 2006 Jul 15;66(14):7237-44.


Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.

Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M, Rodriguez R.

J Biomed Biotechnol. 2012;2012:180363. doi: 10.1155/2012/180363. Epub 2012 Oct 2.


Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.

Tran LNK, Kichenadasse G, Sykes PJ.

Curr Cancer Drug Targets. 2018 Jul 23. doi: 10.2174/1568009618666180724111604. [Epub ahead of print]


Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.

Zhang X, Zhang X, Huang T, Geng J, Liu M, Zheng J.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2823-8. eCollection 2015.


Does valproic acid induce neuroendocrine differentiation in prostate cancer?

Sidana A, Wang M, Chowdhury WH, Toubaji A, Shabbeer S, Netto G, Carducci M, Lupold SE, Rodriguez R.

J Biomed Biotechnol. 2011;2011:607480. doi: 10.1155/2011/607480. Epub 2010 Oct 25.


Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.

Wedel S, Hudak L, Seibel JM, Juengel E, Oppermann E, Haferkamp A, Blaheta RA.

Prostate. 2011 May 15;71(7):722-35. doi: 10.1002/pros.21288. Epub 2010 Oct 15.


Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.

Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, Hintereder G, Blaheta RA.

J Cell Mol Med. 2009 Aug;13(8B):2342-52. doi: 10.1111/j.1582-4934.2008.00603.x.


Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.

Shirsath N, Rathos M, Chaudhari U, Sivaramakrishnan H, Joshi K.

Lung Cancer. 2013 Nov;82(2):214-21. doi: 10.1016/j.lungcan.2013.08.010. Epub 2013 Sep 3.


Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.

Wedel S, Hudak L, Seibel JM, Makarević J, Juengel E, Tsaur I, Waaga-Gasser A, Haferkamp A, Blaheta RA.

BMC Cancer. 2011 Aug 25;11:375. doi: 10.1186/1471-2407-11-375.


Antitumour effect of valproic acid against salivary gland cancer in vitro and in vivo.

Nagai H, Fujioka-Kobayashi M, Ohe G, Hara K, Takamaru N, Uchida D, Tamatani T, Fujisawa K, Miyamoto Y.

Oncol Rep. 2014 Mar;31(3):1453-8. doi: 10.3892/or.2013.2959. Epub 2013 Dec 31.


New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.

Wedel SA, Sparatore A, Soldato PD, Al-Batran SE, Atmaca A, Juengel E, Hudak L, Jonas D, Blaheta RA.

J Cell Mol Med. 2008 Dec;12(6A):2457-66. doi: 10.1111/j.1582-4934.2008.00271.x. Epub 2008 Feb 8.


Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo.

Wang D, Jing Y, Ouyang S, Liu B, Zhu T, Niu H, Tian Y.

Oncol Lett. 2013 Nov;6(5):1492-1498. Epub 2013 Sep 6.


Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells.

Thotala D, Karvas RM, Engelbach JA, Garbow JR, Hallahan AN, DeWees TA, Laszlo A, Hallahan DE.

Oncotarget. 2015 Oct 27;6(33):35004-22. doi: 10.18632/oncotarget.5253.

Supplemental Content

Support Center